GlassScriptPhysician profile
Zachary Leshen
NPI 1285646729
$9,234.88
in general payments reported to CMS, 2019-2025
44 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $791 · 2021: $866 · 2022: $1,738 · 2023: $1,148 · 2024: $1,448 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,349.50 | 2019-2025 | |
| Pfizer INC. | $960.12 | 2019-2025 | |
| Amgen INC. | $667.24 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $646.65 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Abiomed | $575.10 | 2019-2025 | Impella |
| Boston Scientific Corporation | $555.83 | 2021-2025 | Watchman Access System, General - Balloon Catheters, Watchman Flx |
| Abbott Laboratories | $397.95 | 2019-2025 | Cardiomems, Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $395.47 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.14 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $340.37 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $338.26 | 2022-2025 | Verquvo, Keytruda |
| Sanofi-Aventis U.S. LLC | $326.62 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $280.52 | 2022-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.11 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $230.78 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $148.46 | 2020-2023 | Diamondback Coronary |
| Cvrx, INC. | $130.88 | 2024 | Barostim Neo System |
| Shockwave Medical, INC | $121.04 | 2022-2025 | |
| Irhythm Technologies, INC. | $113.71 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Scientific Affairs, LLC | $110.70 | 2019 | |
| Penumbra, INC. | $105.51 | 2023-2024 | Penumbra System, Indigo System |
| Amarin Pharma, INC. | $96.03 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $92.06 | 2024 | Arcalyst |
| Chiesi USA, INC. | $64.20 | 2020-2022 | |
| Scpharmaceuticals INC. | $64.17 | 2023-2025 | |
| Medtronic Vascular, INC. | $49.67 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $43.53 | 2023 | Arcalyst |
| Vital Connect, INC | $39.72 | 2024 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $39.58 | 2022 | |
| Cardiva Medical, INC. | $39.56 | 2020-2022 | |
| Philips North America LLC | $37.26 | 2024-2025 | (Bq9) Coronary Ivus, Encore |
| W. L. Gore & Associates, INC. | $36.45 | 2022 | |
| Astellas Pharma US INC | $35.88 | 2021-2022 | |
| Glaxosmithkline, LLC. | $30.60 | 2025 | Shingrix, Arexvy |
| Veryan Medical Incorporated | $22.60 | 2024 | Biomimics 3d Vascular Stent System |
| Lexicon Pharmaceuticals, INC. | $22.30 | 2023 | Inpefa |
| Angiodynamics, INC. | $19.86 | 2020 | |
| Octapharma USA, INC. | $19.83 | 2025 | Fibryga |
| Elutia, INC. | $18.09 | 2022 | |
| Surmodics, INC. | $15.63 | 2022 | |
| Terumo Medical Corporation | $14.26 | 2019 | |
| Medtronic, INC. | $13.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.38 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Leshen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.